A Phase 1, Open-label, Study of Voruciclib in Subjects With Relapsed and/or Refractory B Cell Malignancies After Failure of Prior Standard Therapies

Trial Profile

A Phase 1, Open-label, Study of Voruciclib in Subjects With Relapsed and/or Refractory B Cell Malignancies After Failure of Prior Standard Therapies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2018

At a glance

  • Drugs Voruciclib (Primary)
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma
  • Focus Adverse reactions
  • Sponsors MEI Pharma
  • Most Recent Events

    • 11 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 15 Nov 2017 New trial record
    • 08 Nov 2017 MEI Pharma Expecting to initiate this trial in the second quarter of 2018, as reported in a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top